In vivo neutralization of tumor necrosis factor-alpha and interferon-gamma abrogates resistance to Yersinia enterocolitica infection in mice
- PMID: 1287419
- DOI: 10.1007/BF00191545
In vivo neutralization of tumor necrosis factor-alpha and interferon-gamma abrogates resistance to Yersinia enterocolitica infection in mice
Abstract
Cytokines are important mediators of the inflammatory host response against infectious agents. In this study, the role of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) in the elimination of a primary infection with highly virulent Yersinia enterocolitica serotype 0:8 strain WA-P has been investigated in C57BL/6 mice. The injection of anti-TNF-alpha or anti-IFN-gamma antibodies ("serotherapy") prior to the intravenous challenge of a sublethal dose of Y. enterocolitica caused an increased bacterial net-growth in the spleens, although this effect was more pronounced for anti-TNF-alpha treatment. The later treatment with anti-TNF-alpha or anti-IFN-gamma antibodies on day 3 post infection likewise abrogated resistance to Y. enterocolitica and, subsequently, led to death from progressive infection. Our data demonstrate for the first time that the endogenous production of both the cytokines TNF-alpha and IFN-gamma is required for the restriction of a primary Y. enterocolitica infection in mice.
Similar articles
-
Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains.Infect Immun. 1998 May;66(5):2213-20. doi: 10.1128/IAI.66.5.2213-2220.1998. Infect Immun. 1998. PMID: 9573110 Free PMC article.
-
IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.J Immunol. 1996 Feb 15;156(4):1458-68. J Immunol. 1996. PMID: 8568248
-
Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon.Infect Immun. 1994 Jun;62(6):2590-9. doi: 10.1128/iai.62.6.2590-2599.1994. Infect Immun. 1994. PMID: 8188382 Free PMC article.
-
Galectin-1-Driven Tolerogenic Programs Aggravate Yersinia enterocolitica Infection by Repressing Antibacterial Immunity.J Immunol. 2017 Aug 15;199(4):1382-1392. doi: 10.4049/jimmunol.1700579. Epub 2017 Jul 17. J Immunol. 2017. PMID: 28716827
-
Experimental Yersinia enterocolitica infection in rodents: a model for human yersiniosis.APMIS. 1993 Jun;101(6):417-29. APMIS. 1993. PMID: 8363822 Review.
Cited by
-
Tumor necrosis factor receptor p55-deficient mice respond to acute Yersinia enterocolitica infection with less apoptosis and more effective host resistance.Infect Immun. 2000 Mar;68(3):1243-51. doi: 10.1128/IAI.68.3.1243-1251.2000. Infect Immun. 2000. PMID: 10678933 Free PMC article.
-
Susceptibility of four inbred mouse strains to a low-pathogenic isolate of Yersinia enterocolitica.Mamm Genome. 2008 Apr;19(4):279-91. doi: 10.1007/s00335-008-9105-1. Epub 2008 Apr 5. Mamm Genome. 2008. PMID: 18392655
-
Comparison of cytokine immune responses to Brucella abortus and Yersinia enterocolitica serotype O:9 infections in BALB/c mice.Infect Immun. 2013 Dec;81(12):4392-8. doi: 10.1128/IAI.00856-13. Epub 2013 Sep 16. Infect Immun. 2013. PMID: 24042115 Free PMC article.
-
Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12.Infect Immun. 1996 Aug;64(8):2955-61. doi: 10.1128/iai.64.8.2955-2961.1996. Infect Immun. 1996. PMID: 8757820 Free PMC article.
-
Development of in vitro correlate assays of immunity to infection with Yersinia pestis.Clin Vaccine Immunol. 2007 May;14(5):605-16. doi: 10.1128/CVI.00398-06. Epub 2007 Mar 21. Clin Vaccine Immunol. 2007. PMID: 17376861 Free PMC article. Clinical Trial.